Drug Approval | November 21, 2025
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Subscribe To Our Newsletter & Stay Updated
